CHICAGO, IL USA (UroToday.com) - Presented by Evan Y. Yu, MD at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA
Slide Lecture: Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302
Poster: Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302
University of Washington
Fred Hutchinson Cancer Research Center
Evan Y. Yu, MD, is a medical oncologist specializing in prostate, bladder, and testicular cancer treatment and research. He graduated Alpha Omega Alpha from the University of Washington School of Medicine and his post-doctoral training was at Harvard Medical School. He completed internal medicine residency at the Brigham and Women’s Hospital and oncology fellowship at the Dana-Farber Cancer Institute. He returned to Seattle at the end of 2004 to join the faculty at the University of Washington and Fred Hutchinson Cancer Research Center.
His research focuses on testing the next wave of novel molecular targeted therapies, with a particular focus on bone-targeted agents. He has also performed novel molecular imaging with PET to evaluate treatment response in bone metastases to systemic therapies in patients with prostate cancer. In addition to an active clinical practice, he also is the Assistant Fellowship Director and remains very active in student, resident, and fellow education.
He has regularly been voted a “Top Doctor” by Castle Connolly, U.S. News and World Report, Seattle magazine, and Seattle Met magazine.